UW–Madison researchers have developed a powerful immunity-boosting postoperative treatment that could transform the odds for patients with glioblastoma.
health & medicine
Flashing lights may provide vital first test of MS drug success
Measuring changes in the speed of electrical signals along nerves connecting the eyes to the brain may accurately reflect recovery from myelin loss in multiple sclerosis (MS), according to new UW-Madison research.
It’s not a shock: Better bandage promotes powerful healing
The bandage developed by UW-Madison engineers leverages energy generated from a patient’s own body motions to apply gentle electrical pulses at the site of an injury.
To help kids battling a rare disease, scientists forge a genetic link between people and pigs
Scientists and physicians needed a better model to understand neurofibromatosis in order to help affected children. A groundbreaking research partnership at UW–Madison is showing the way.
To help kids battling a rare disease, scientists forge a genetic link between people and pigs
Scientists and physicians needed a better model to understand neurofibromatosis in order to help affected children. A groundbreaking research partnership at UW–Madison is showing the way.
UW scientists find key cues to regulate bone-building cells
The prospect of regenerating bone lost to cancer or trauma is a step closer to the clinic.
Morgridge–UW project investigates tissue-engineered arteries for transplant
The prospect of creating artery “banks” could transform treatment of many common heart and vascular ailments. But it’s a big leap from concept to reality.
Madison startup advances three-in-one cancer drug rooted at UW
The first target for Co-D is angiosarcoma, a rare and lethal cancer that arises from blood vessels.
Stem cell ‘heart patch’ moves closer to clinic
The promise of stem cells to treat cardiovascular disease may soon be a step closer to overcoming the last big hurdle before trials in human patients.
UW-Madison spinoff gets FDA OK for bacteria-killing wound dressing
Microlyte, patented by Imbed Biosciences, will compete in the $2 billion market sector of “advanced wound dressings,” which are used to treat ulcers, burns, bedsores and other difficult wounds.